Skip to main content
SpringerLink
Log in

Goals of Antihypertensive Therapy

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Antihypertensive therapy has been used for almost 40 years to reduce blood pressure and to prevent morbidity and mortality related to the hypertensive state. Cardiovascular events are related to the initial elevation of blood pressure; the benefits of treating malignant, severe or moderate hypertension are well established. Although large scale clinical trials have demonstrated a decrease in morbid events when mildly elevated blood pressures is treated, the benefits are neither universal or dramatic and treatment is certainly less cost effective than no treatment.

Recently it has been emphasised that the absolute risk of cardiovascular events is determined only in part by blood pressure, and that it is also influenced by age, gender, race and the presence of other cardiovascular risk factors. For example, in older individuals where the absolute risk of vascular complications is greater than in younger individuals for any given level of blood pressure, the benefits of therapy will be greater. It has been suggested that in younger individuals with mild hypertension and a low absolute risk of developing cardiovascular morbid events it may be more appropriate to monitor the effects of drug therapy on measures of cardiac and vascular damage that are associated with the hypertensive state.

Drug therapy has been shown to be extremely effective in reducing the incidence of stroke, congestive cardiac failure and renal failure associated with elevated blood pressure. Meta-analysis of randomised large scale clinical trials indicates that drug therapy may not reduce coronary events to the extent expected in patients with hypertension. One plausible explanation is that the trials have been of insufficient duration to detect the benefit of blood pressure lowering on coronary heart disease. It has also been suggested that certain adverse metabolic effects associated with the use of thiazide diuretics and β-blockers employed in these trials may have partially offset the benefits of blood pressure reduction. However, the clinical significance of these drug-induced metabolic disturbances remains unclear. Experimental data suggesting differences in the ability of antihypertensive drugs to inhibit atherosclerosis in animal models are also of interest, but again the relation of the findings to the clinical situation is unknown.

Thiazide diuretics, β-blockers, calcium antagonists, angiotensin-converting enzyme (ACE) inhibitors and α-blockers can produce regression of left ventricular hypertrophy (LVH). While LVH is clearly a strong and independent predictor for coronary disease, it remains to be shown that a lower risk for coronary morbid events exists in patients whose LVH has undergone regression over and above that attributable to blood pressure reduction. Thus, although ACE inhibitors, calcium antagonists and α-blockers may have some advantages for the prevention of cardiovascular disease progression, until randomised trials show that they are more effective than diuretics or β-blockers in terms of preventing cardiovascular events, they should probably be considered as second-line treatment for patients with mild hypertension.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hodge JV, Smirk FH. The effect of drug treatment of hypertension on the distribution of deaths from various causes. Am Heart J 1967; 73: 441–52.

    Google Scholar 

  2. Subcommittee of the WHO/ISH Hypertension Liaison Committee. 1993 guidelines for the management of mild hypertension: memorandum from a World Health Organization/International Society of Hypertension meeting. Hypertension 1993; 22: 392–403.

    Google Scholar 

  3. Kannel WB. Hypertension: relationship with other risk factors. Drugs 1986; 32 Suppl. 1: 1–11.

    Google Scholar 

  4. Bulpitt CJ. A risk-benefit analysis for the treatment of hypertension. Postgrad Med J 1993; 69: 764–74.

    PubMed  CAS  Google Scholar 

  5. Sever P, Beevers G, Bulpitt C, et al. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ 1993; 306: 983–7.

    PubMed  CAS  Google Scholar 

  6. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993; 153: 154–83.

    Google Scholar 

  7. Petrie JC, o’Brien ET, Littler WA, et al. British Hypertension Society recommendations on blood pressure measurement. BMJ 1986; 293: 611–5.

    PubMed  CAS  Google Scholar 

  8. Perloff D, Grim C, Flack JM, et al. Human blood pressure determination by sphygmomanometry. Circulation 1993; 88 (5 Part 1): 2460–70.

    PubMed  CAS  Google Scholar 

  9. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. The 1988 report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1988; 148: 1023–38.

    Google Scholar 

  10. Kannel WB. Hypertension as a risk factor for cardiac events — epidemiologic results of long-term studies. J Cardiovasc Pharmacol 1993; 21 Suppl. 2: S27–37.

    PubMed  Google Scholar 

  11. Jackson R, Barham P, Bills J, et al. Management of raised blood pressure in New Zealand: a discussion document. BMJ 1993; 307: 107–10.

    PubMed  CAS  Google Scholar 

  12. Jackson R. Which hypertensive patients should be treated? Lancet 1994; 343: 496–7.

    PubMed  CAS  Google Scholar 

  13. MacMahon SW, Cutler JA, Furberg CD, et al. The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized controlled trials. Prog Cardiovasc Dis 1986; 29 Suppl. 1: 99–118.

    PubMed  CAS  Google Scholar 

  14. MacMahon S, Peto R, Culter J, et al. Blood pressure, stroke and coronary heart disease. Part 1: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765–74.

    PubMed  CAS  Google Scholar 

  15. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke and coronary heart disease: part 2; short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990; 335: 827–38.

    PubMed  CAS  Google Scholar 

  16. Swales JD. New antihypertensive agents: benefit of treatment. J Cardiovasc Pharmacol 1992; 20 Suppl. 11: 570–3.

    Google Scholar 

  17. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1991; 265: 3255–64.

    Google Scholar 

  18. Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in old patients with hypertension (STOP-Hypertension). Lancet 1991; 338: 1281–5.

    PubMed  CAS  Google Scholar 

  19. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405–12.

    Google Scholar 

  20. MacMahon S, Rodgers A. The effects of antihypertensive treatment on vascular disease: reappraisal of the evidence in 1994. J Vase Medicine Biol 1993; 4: 265–71.

    Google Scholar 

  21. Weber MA, Laragh JH. Hypertension: steps forward and steps backward. Arch Intern Med 1993; 153: 149–52.

    PubMed  CAS  Google Scholar 

  22. Gavras H, Gavras I. On the JNC V Report: a different point of view. Am J Hypertens 1994; 7: 288–93.

    PubMed  CAS  Google Scholar 

  23. Zanchetti A. Goals of antihypertensive treatment: prevention of cardiovascular events and prevention of organ damage. Blood Press 1992; 1: 205–11.

    PubMed  CAS  Google Scholar 

  24. Multiple Risk Factor Intervention Trial Research Group. Baseline rest electrocardiographic abnormalities, antihypertensive treatment and mortality in the multiple risk factor intervention trial. Am J Cardiol 1985; 55: 1–15.

    Google Scholar 

  25. Poulter NB. Management of multiple risk factors on coronary heart disease in patients with hypertension. Am Heart J 1991; 121: 246–50.

    PubMed  CAS  Google Scholar 

  26. Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet 1987; i: 581–4.

    Google Scholar 

  27. Zanchetti A. Short and long-term perspectives of antihypertensive therapy. An Introduction. Am J Hypertens 1993; 6: 2S–5S.

    PubMed  CAS  Google Scholar 

  28. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressure averaging 115 through 129mm Hg. JAMA 1967; 202: 1028–34.

    Google Scholar 

  29. Veterans Administration Cooperative Study Group on Hypertension. Effects of treatment on morbidity in hypertension. II: results in patients with diastolic blood pressure averaging 90 through 114mm Hg. JAMA 1970; 213: 1143–52.

    Google Scholar 

  30. New trials in older hypertensives [editorial]. Lancet 1991; 338: 1299–300.

  31. Luft FC, Mann JFE. New classes of antihypertensive drugs and new findings with established agents. Curr Opin Nephrol Hypertens 1992; 1: 91–9.

    PubMed  CAS  Google Scholar 

  32. Kannel WB. Hypertension and the risk of cardiovascular disease, In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis, and management. New York: Raven Press, 1990: 101–17.

    Google Scholar 

  33. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561–6.

    PubMed  CAS  Google Scholar 

  34. Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114: 345–52.

    PubMed  CAS  Google Scholar 

  35. Shulman NB, Ford CE, Hall WD, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Hypertension 1989; 13 Suppl. 1: 80–93.

    Google Scholar 

  36. Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension 1992; 19: 403–18.

    PubMed  CAS  Google Scholar 

  37. Cruickshank JM. Coronary flow reserve and the J-curve relation between diastolic blood pressure and myocardial infarction. BMJ 1988; 297: 1227–30.

    PubMed  CAS  Google Scholar 

  38. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction; an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335–71.

    PubMed  CAS  Google Scholar 

  39. Pfeffer M, Braunwald E, Moye L, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327: 677–99.

    Google Scholar 

  40. Flack JM, McVeigh GE, Grimm RH. Hypertension therapy in the elderly. Curr Opin Nephrol Hypertens 1993; 2: 386–94.

    PubMed  CAS  Google Scholar 

  41. McVeigh G, Galloway D, Johnston D. The case for low dose diuretics in hypertension: comparison of low and conventional doses of cyclopenthiazide. BMJ 1988; 297: 95–8.

    PubMed  CAS  Google Scholar 

  42. Johnston GD. Selecting appropriate antihypertensive drug dosages. Drugs 1994; 47 (4): 567–75.

    PubMed  CAS  Google Scholar 

  43. Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304: 801–7.

    Google Scholar 

  44. Beta Blocker Heart Attack Study Group. The Beta Blocker Heart Attack trial. JAMA 1981; 246: 2073–4.

    Google Scholar 

  45. Beta Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction: 1. Mortality results. JAMA 1982; 247: 1707–13.

    Google Scholar 

  46. Olsson G, Lubsen J, Van Es G, et al. Quality of life after myocardial infarction: Effect of long-term metoprolol on morbidity and mortality. BMJ 1986; 292: 1491–3.

    PubMed  CAS  Google Scholar 

  47. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ 1985; 291: 97–104.

    Google Scholar 

  48. Wilhelmson L, Berglund G, Elmfeldt D, et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY Trial. J Hypertens 1987; 5: 561–72.

    Google Scholar 

  49. The IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertens 1985; 3: 379–92.

    Google Scholar 

  50. Tifft CP, Chobanian AV. Are some antihypertensive therapies more efficacious than others in preventing complications and prolonging life? Hypertension 1991; 18 Suppl. 1:I146–52.

    PubMed  CAS  Google Scholar 

  51. MacMahon S. Blood pressure reduction and the prevention of stroke. J Hypertens 1991; 9 Suppl. 7: S7–10.

    CAS  Google Scholar 

  52. Isles CG, Brown JJ, Lever AF, et al. What clinical trials have taught us. In: Buhler FR, Laragh JH, editors. Handbook of hypertension: the management of hypertension. Vol 13. Amsterdam: Elsevier 1990: 18–32.

    Google Scholar 

  53. Beard R, Bulpitt C, Mascie-Taylor H, et al. Management of elderly patients with sustained hypertension. BMJ 1992; 304: 412–6.

    PubMed  CAS  Google Scholar 

  54. Neaton JD, Grimm Jr RH, Prineas RJ, et al. Treatment of Mild Hypertension Study Final Results. JAMA 1993; 270: 713–24.

    PubMed  CAS  Google Scholar 

  55. Carlsen JE, Kober L, Torp-Pederson L, et al. Relation between dose of bendrofluazide, antihypertensive effect and adverse biochemical effects. BMJ 1990; 300: 975–8.

    PubMed  CAS  Google Scholar 

  56. Morgan DB, Davidson C. Hypokalemia and diuretics: an analysis of publications. BMJ 1980; 280: 905–8.

    PubMed  CAS  Google Scholar 

  57. Johnston GD, Wilson R, McDermott BJ, et al. Low-dose cyclopenthiazide in the treatment of hypertension: a one-year community-based study. Q J Med 1991; 286: 135–43.

    Google Scholar 

  58. Grimm RH, Cohen JD, Smith WM, et al. Hypertension management in the multiple risk factor intervention trial (MRFIT): six year intervention results for men in special intervention and usual care groups. Arch Intern Med 1985; 145: 1191–9.

    PubMed  Google Scholar 

  59. Tweeddale MG, Oglivie RI, Ruedy J. Antihypertensive and biochemical effects of chlorthalidone. Clin Pharmacol Ther 1977; 22: 519–27.

    PubMed  CAS  Google Scholar 

  60. Hollfield JW. Thiazide treatment of hypertension: effects of thiazide diuretics on serum potassium, magnesium and ventricular ectopy. Am J Med 1986; 80 Suppl. 4A: 8–12.

    Google Scholar 

  61. Cohen JD, Neaton JD, Prineas RJ, et al. Diuretics, serum potassium and ventricular arrhythmias in the multiple risk factor intervention trial. Am J Cardiol 1987; 60: 548–54.

    PubMed  CAS  Google Scholar 

  62. Singh BN, Hollenberg NK, Poole-Wilson PA, et al. Diuretic-induced potassium and magnesium deficiency: relation to drug-induced QT prolongation, cardiac arrhythmias and sudden death. J Hypertens 1992; 10: 301–16.

    PubMed  CAS  Google Scholar 

  63. Whelton PK, Watson AJ. Diuretic-induced hypokalemia and cardiac arrhythmias. Am J Cardiol 1986; 58: 5A–10A.

    PubMed  CAS  Google Scholar 

  64. Mclnnes GT, Yeo WW, Ramsay LE, et al. Cardiotoxicity and diuretics: much speculation — little substance. J Hypertens 1992; 10: 317–35.

    Google Scholar 

  65. Freis E. The cardiotoxicity of thiazide diuretics: review of the evidence. J Hypertens 1990; 8 Suppl. 2: 23–32.

    Google Scholar 

  66. Goldner MG, Zarowitz M, Akgun S. Hyperglycemia and glycosuria due to thiazide derivatives administered in diabetes mellitus. N Engl J Med 1960; 262: 403–5.

    PubMed  CAS  Google Scholar 

  67. Medical Research Council Working Party on Mild to Moderate Hypertension. Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Lancet 1981; 2: 539–43.

    Google Scholar 

  68. Furman BL. Impairment of glucose tolerance produced by diuretics and other drugs. Pharmacol Ther 1981; 12 (3): 613–49.

    PubMed  CAS  Google Scholar 

  69. Ramsay LE, Yeo WW, Jackson PR. Influence of diuretics, calcium antagonists, and alpha-blockers on insulin sensitivity and glucose intolerance in hypertensive patients. J Cardiovasc Pharmacol 1992; 20 Suppl. 11: S49–54.

    PubMed  Google Scholar 

  70. Passmore AP, Whitehead EM, Crawford V, et al. The antihypertensive and metabolic effects of low and conventional dose cyclopenthiazide in type II diabetics with hypertension. Q J Med 1991; 295: 919–28.

    Google Scholar 

  71. Helgeland A, Strommen R, Hagelund CH, et al. Enalapril, atenolol and hydrochlorothiazide in mild to moderate hypertension. Lancet 1986; 1: 872–5.

    PubMed  CAS  Google Scholar 

  72. Law MR, Wald NJ, Hackshaw A, et al. Systemic underestimation of association between serum cholesterol concentration and ischemic heart disease in observational studies: data from the BUPA study. BMJ 1994; 308: 363–6.

    PubMed  CAS  Google Scholar 

  73. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994; 308: 367–72.

    PubMed  CAS  Google Scholar 

  74. Marmot M. The cholesterol papers. BMJ 1994; 308: 351–2.

    PubMed  CAS  Google Scholar 

  75. Ames RA. The effects of antihypertensive drugs on serum lipids and lipoproteins I. Diuretics. Drugs 1986; 32: 260–78.

    PubMed  CAS  Google Scholar 

  76. Flack JM, Grimm Jr RH. Diuretics. In: Kaplan NM, Brenner DM, Laragh EH, editors. New therapeutic strategies in hypertension. New York: Raven Press, 1989: 17.

    Google Scholar 

  77. Bradley K, Flack JM, Belcher J, et al. Chlorthalidone attenuates the reduction in small, dense LDL cholesterol subclass associated with weight loss. Am J Hypertens 1993; 6: 636–9.

    PubMed  CAS  Google Scholar 

  78. MacMahon SW, MacDonald GJ, Blacker RB. Plasma lipoprotein levels in treated and untreated hypertensive men and women. The national heart foundation of Australia Risk Factor Prevalence Study. Arteriosclerosis 1984; 5 (4): 391–6.

    Google Scholar 

  79. Grimm Jr RH, Leon AS, Hunninghake DB, et al. Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients. A double blind controlled trial. Ann Intern Med 1981; 94: 7–11.

    PubMed  Google Scholar 

  80. Berglund G, Andersson O. Beta-blockers or diuretics in hypertension? A six-year follow-up of blood pressure and metabolic side-effects. Lancet 1981; 1: 744–7.

    PubMed  CAS  Google Scholar 

  81. Helgeland A, Hjermann I, Leren P, et al. High density lipoprotein-cholesterol and antihypertensive drugs: the Oslo study. BMJ 1978; 2: 403–6.

    PubMed  CAS  Google Scholar 

  82. Multiple Risk Factor Intervention Trial. Risk factor changes and mortality results. JAMA 1982; 248: 1465–77.

    Google Scholar 

  83. Materson BJ, Reda DJ, Cushman WC, et al. Antihypertensive agents. N Engl J Med 1993; 328: 914–21.

    PubMed  CAS  Google Scholar 

  84. Burris JF, Neir MR, Oparil S, et al. An assessment of diltiazem and hydrochlorothiazide in hypertension. JAMA 1990; 263: 1507–12.

    PubMed  CAS  Google Scholar 

  85. Waller PC, Ramsay LE. Predicting acute gout in diuretic treated hypertensive patients. J Hum Hypertens 1989; 3: 457–61.

    PubMed  CAS  Google Scholar 

  86. Ramsay LE, Yeo WW, Jackson PR. Thiazide diuretics: first-line therapy for hypertension. J Hypertens 1992; 10 Suppl. 3: S29–33.

    CAS  Google Scholar 

  87. Ramsay LE. Diuretic drugs. In: Dukes MNG, editor. Side effects of drugs annual II. Amsterdam: Elsevier Science Publishers, 1987: 193–202.

    Google Scholar 

  88. Wassertheil-Smoller S, Oberman A, Blaufox DM, et al. The trial of antihypertensive interventions and management (TAIM) study: final results with regard to blood pressure, cardiovascular risk, and quality of life. Am J Hypertens 1992; 5: 37–44.

    PubMed  CAS  Google Scholar 

  89. Dahlof B, Hansson L. Regression of left ventricular hypertrophy in previously untreated essential hypertension: different effects of enalapril and hydrochlorothiazide. J Hypertens 1992; 10: 1513–24.

    PubMed  CAS  Google Scholar 

  90. Devereux RB, de Simone G, Ganau A, et al. Left ventricular hypertrophy associated with hypertension and its relevance as a risk factor for complications. J Cardiovasc Pharmacol 1993; 21 Suppl. 2: S38–44.

    PubMed  Google Scholar 

  91. Clement DL, DeBuyzere M, Duprez D. Left ventricular function and regression of left ventricular hypertrophy in essential hypertension. Am J Hypertens 1993; 6: 14S–9S.

    PubMed  CAS  Google Scholar 

  92. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies. Am J Hypertens 1992; 5: 95–110.

    PubMed  CAS  Google Scholar 

  93. Korner PI. Some thoughts on pathogenesis therapy and prevention of hypertension. Blood Press 1994; 3: 7–17.

    PubMed  CAS  Google Scholar 

  94. Cooper A, Heagerty A. Small arteries and hypertension. J Hypertens 1994; 12 Suppl. 1: S33–5.

    CAS  Google Scholar 

  95. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Propranolol or hydrochlorothiazide alone for the initial treatment of hypertension: IV. Effect on plasma glucose and glucose tolerance. Hypertension 1985; 7: 1008–16.

    Google Scholar 

  96. Sawicki PT, Berger M. Effects of antihypertensive treatment with alpha-blockers on glucose metabolism. J Cardiovasc Pharmacol 1992; 20 Suppl. 11: S45–9.

    PubMed  Google Scholar 

  97. Prichard BNC, Smith CCT, Sen S, et al. Hypertension and insulin resistance. J Cardiovasc Pharmacol 1992; 20 Suppl. 11: S77–84.

    PubMed  Google Scholar 

  98. Northcote RJ, Todd IC, Ballantyne D. Beta-blockers and lipoproteins: a review of current knowledge. Scot Med J 1986; 31: 220–8.

    PubMed  CAS  Google Scholar 

  99. Omoigui N, Dzau VJ. Differential effects of antihypertensive agents in experimental and human atherosclerosis. Am J Hypertens 1993; 6: 30S–9S.

    PubMed  CAS  Google Scholar 

  100. Cruickshank JM, Smith JC. The beta-receptor, atheroma and cardiovascular damage. Pharmacol Ther 1989; 42: 385–404.

    PubMed  CAS  Google Scholar 

  101. Northcote RJ. Metabolic parameters: how important are pharmacologically induced changes? J Hypertens 1991; 9 Suppl. 7: S21–5.

    CAS  Google Scholar 

  102. Croog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986; 314: 1657–64.

    PubMed  CAS  Google Scholar 

  103. Fletcher AE, Bulpitt CJ, Hawkins CM, et al. Quality of life on antihypertensive therapy: a randomized double blind controlled trial of captopril and atenolol. J Hypertens 1990; 8: 463–6.

    PubMed  CAS  Google Scholar 

  104. Bulpitt CJ, Fletcher AE. Quality of life evaluation of antihypertensive drugs. PharmacoEconomics 1992; 2: 95–102.

    Google Scholar 

  105. Croog SH, Elias MF, Colton T, et al. Effects of antihypertensive medications on quality of life in elderly hypertensive women. Am J Hypertens 1994; 7: 329–39.

    PubMed  CAS  Google Scholar 

  106. Glasser SP, Koehn DK, Powell R. Regression of left ventricular hypertrophy in treated hypertensive patients with dilevalol and metoprolol — a double blind randomized study. J Clin Pharmacol 1989; 29: 791–7.

    PubMed  CAS  Google Scholar 

  107. Frohlich ED. Left ventricular hypertrophy, cardiac disease and hypertension: recent experiences. J Am Coll Cardiol 1989; 17: 1587–94.

    Google Scholar 

  108. o’Byrne S, Feely J. Effects of drugs on glucose tolerance in non-insulin-independent diabetics (part 1). Drugs 1990; 40: 6–18.

    PubMed  Google Scholar 

  109. Stern N, Tuck M. Drug therapy for hypertension in diabetic patients. J Hum Hypertens 1991; 5: 295–305.

    PubMed  CAS  Google Scholar 

  110. Lehtonen A. Antihypertensive therapy and blood lipids: calcium antagonists. Scand J Clin Lab Invest 1990; 50 Suppl. 199: 49–54.

    Google Scholar 

  111. Buhler FR. The case for calcium antagonists as first-line treatment of hypertension. J Hypertens 1992; 10 Suppl. 3: S17–20.

    CAS  Google Scholar 

  112. Henry PD. Calcium channel blockers and atherosclerosis. J Cardiovasc Pharmacol 1990; 16 Suppl. 1: S12–5.

    PubMed  Google Scholar 

  113. The Israeli SPRINT Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT): a randomized intervention of nifedipine in patients with acute myocardial infarction. Eur Heart Journal 1988; 9: 354–64.

    Google Scholar 

  114. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on Mortality and Reinfarction after myocardial infarction. N Engl J Med 1988; 319: 385–92.

    Google Scholar 

  115. The Danish Study Group on Verapamil in Myocardial Infarction. Effects of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II — DAVIT II). Am J Cardiol 1990; 66: 779–85.

    Google Scholar 

  116. Waters D. Proischemic complications of dihydropyridine calcium-channel blockers. Circulation 1991; 84: 2598–600.

    PubMed  CAS  Google Scholar 

  117. Beto JA, Bansal VK. Quality of life in the treatment of hypertension: a meta-analysis of clinical trials. Am J Hypertens 1992; 5: 125–33.

    PubMed  CAS  Google Scholar 

  118. Torok E, Borbas S, Lengyel M, et al. Regression of cardiac hypertrophy in hypertensive patients by long-term treatment with isradipine. J Cardiovasc Pharmacol 1992; 19 Suppl. 3: S79–83.

    PubMed  Google Scholar 

  119. Szlachcic J, Tuban JF, Vollmer C, et al. Effect of diltiazem on left ventricular mass and diastolic filling in mild to moderate hypertension. Am J Cardiol 1989; 63: 198–201.

    PubMed  CAS  Google Scholar 

  120. Schmieder RE, Messerli FH, Garavaglia GE, et al. Cardiovascular effects of verapamil in patients with essential hypertension. Circulation 1987; 75: 1030–6.

    PubMed  CAS  Google Scholar 

  121. Pollare T, Lithell M, Selinus I, et al. Application of prazosin is associated with an increase in insulin sensitivity in obese patients with hypertension. Diabetologia 1988; 31: 415–20.

    PubMed  CAS  Google Scholar 

  122. Donnelly R. Angiotensin-converting enzyme inhibitors and insulin sensitivity: metabolic effects in hypertension, diabetes and heart failure. J Cardiovasc Pharmacol 1992; 20 Suppl. 11: S38–44.

    PubMed  Google Scholar 

  123. Chandler B, Lavin P. Efficacy and tolerability of enalapril and its effects on serum lipids in patients with mild uncomplicated hypertension. Curr Ther Res 1988; 43: 1143–9.

    Google Scholar 

  124. Weinberger MH. Blood pressure and metabolic responses to hydrochlorothiazide, captopril and the combinations in black and white mild-to-moderate hypertensive patients. J Cardiovasc Pharmacol 1985; 7 Suppl. 1: S52–5.

    PubMed  Google Scholar 

  125. Dzau VJ. Angiotensin converting enzyme inhibitors and the cardiovascular system. J Hypertens 1992; 10 Suppl. 3: S3–10.

    CAS  Google Scholar 

  126. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejections fractions. Lancet 1992; 340: 1173–8.

    PubMed  CAS  Google Scholar 

  127. Stein PP, Black HR. Drug treatment of hypertension in patients with diabetes mellitus. Diabetes Care 1991; 14: 425–8.

    PubMed  CAS  Google Scholar 

  128. Leren P. The cardiovascular effects of alpha-receptor blocking agents. J Hypertens 1992; 10 Suppl. 3: S11–5.

    CAS  Google Scholar 

  129. Thaulow E, Nitter-Hauge S. Antihypertensive therapy and blood lipids: alpha-blockers. Scand J Clin Lab Invest 1990; 50 Suppl. 199: 45–8.

    Google Scholar 

  130. Krone W, Nagele H. Effects of antihypertensives on plasma lipids and lipoprotein metabolism. Am Heart J 1988; 116: 1729–34.

    PubMed  CAS  Google Scholar 

  131. Weinstein MC, Stason WB. Cost-effectiveness of interventions to prevent or treat coronary heart disease. Annu Rev Public Health 1985; 6: 41–3.

    PubMed  Google Scholar 

  132. Littenberg B, Garber AM, Sox Jr HC. Screening for hypertension. Ann Intern Med 1990; 112: 192–202.

    PubMed  CAS  Google Scholar 

  133. Edelson JT, Weinstein MC, Tostenson AWA, et al. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA 1990; 263: 408–13.

    Google Scholar 

  134. Stason WB. Opportunities to improve the cost-effectiveness of treatment for hypertension. Hypertension 1991; 18 Suppl. 1: 1161–6.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of General and Preventive Medicine, University of Minnesota, 420 Delaware Street S.E., Box 741 UMHC, Minneapolis, Minnesota, 55455, USA

    Gary E. McVeigh & John Flack

  2. Department of Cardiology, University of Minnesota, Minneapolis, Minnesota, USA

    Richard Grimm

Authors
  1. Gary E. McVeigh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Flack
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard Grimm
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

McVeigh, G.E., Flack, J. & Grimm, R. Goals of Antihypertensive Therapy. Drugs 49, 161–175 (1995). https://doi.org/10.2165/00003495-199549020-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199549020-00002

Keywords

Search

Navigation